Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Kezar Life Sciences, Inc. (KZR) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
Docs: "Investor Contact: Gitanjali Jain Vice President, Investor Relations and External Affairs"
08/10/2023 8-K Quarterly results
Docs: "Investor Contact:"
07/26/2023 8-K Quarterly results
06/16/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "KEZAR LIFE SCIENCES, INC."
05/11/2023 8-K Quarterly results
Docs: "Investor Contact:"
04/27/2023 8-K Quarterly results
02/28/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/09/2023 8-K Results of Operations and Financial Condition  Interactive Data
11/10/2022 8-K Quarterly results
Docs: "Investor Contact:"
11/03/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
07/11/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
05/13/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/03/2022 8-K Quarterly results
03/17/2022 8-K Quarterly results
Docs: "Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update • Topline data from two Phase 2 trials of KZR-616 expected in second quarter of 2022 • Zetomipzomib assigned as nonproprietary name for lead candidate, KZR-616 • Cash, cash equivalents and marketable securities totaled $208.4 million as of year-end 2021 SOUTH SAN FRANCISCO, Calif. – – March 17, 2022 – Kezar Life Sciences, Inc., , a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a business update. “In 2021, we made significant progress in each of our programs, achieving target enrollmen..."
01/07/2022 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
12/20/2021 8-K Termination of a Material Definitive Agreement, Results of Operations and Financial Condition  Interactive Data
12/10/2021 8-K Quarterly results
11/19/2021 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financi...
Docs: "Sales Agreement, between the Company and Cowen and Company, LLC",
"Opinion of Cooley LLP"
11/15/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Presentation",
"Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis"
11/09/2021 8-K Quarterly results
Docs: "Kezar Reports Third Quarter Financial Results and Provides Business Update"
08/12/2021 8-K Quarterly results
Docs: "Kezar Life Sciences Reports Second Quarter Financial Results and Provides Business Updates"
06/30/2021 8-K Quarterly results
06/02/2021 8-K Quarterly results
06/01/2021 8-K Quarterly results
05/12/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Cash, cash equivalents and marketable securities totaled $150.0 million as of September 30, 2020, compared to $78.2 million as of December 31, 2019. The increase in cash, cash equivalents and marketable securities was primarily attributable to the net proceeds from Kezar’s underwritten public offerings in February and June 2020, net of cash used by the Company in operations to advance its clinical stage programs and preclinical research and development. • Research and development expenses for the third quarter of 2020 increased by $1.2 million to $8.3 million, compared to $7.1 million in the third quarter of 2019. This increase was primarily related to advancing both the KZR-616 clinical program in multiple indications and the protein secretion preclinical program. • General ..."
08/05/2020 8-K Quarterly results
06/26/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy